Myocardial damage to severe pneumococcal pneumonia as a cause of death from acute cardiovascular events (NEUMOCAR) (Q3205034)

From EU Knowledge Graph
Revision as of 08:24, 14 October 2021 by DG Regio (talk | contribs) (‎Changed label, description and/or aliases in en: translated_label)
Jump to navigation Jump to search
Project Q3205034 in Spain
Language Label Description Also known as
English
Myocardial damage to severe pneumococcal pneumonia as a cause of death from acute cardiovascular events (NEUMOCAR)
Project Q3205034 in Spain

    Statements

    0 references
    20,750.0 Euro
    0 references
    41,500.0 Euro
    0 references
    50.0 percent
    0 references
    1 January 2017
    0 references
    31 March 2020
    0 references
    FUNDACION INSTITUTO DE INVESTIGACION SANITARIA PERE VIRGILI
    0 references
    0 references

    41°7'2.06"N, 1°15'16.60"E
    0 references
    43148
    0 references
    Hipótesis: Los eventos cardiovasculares (ECV) de novo en pacientes con neumonía comunitaria grave (NCG) son frecuentes (17%) y pudieran estar relacionados con la invasión directa del neumococo en miocardio , con la liberación de tóxinas (neumolisina ) o bien con la exposición a proteína endógenas liberadas por el sistema inmune (histonas, NETs, IL-1b, h-Fabp). La frecuencia de aparición y su impacto en la evolución en pacientes sin cardiopatía previa (CP) no ha sido estudiada. Objetivos:1) Determinar la incidencia de daño miocardico agudo (DMA) y ECV en pacientes con NCG sin CP valorada por métodos no invasivos (Eco y Resonancia MN) y biomarcadores (Tn-I, h-Fabp, NT-proBNP, histonas, NETs, IL 1b, h-Fabp); 2) Valorar si el DMA y ECV se relaciona con el patógeno causal de la CAP y su impacto sobre evolución y 3) Investigar la presencia de fibrosis miocárdica mediante RMN y su relación con la etiología y DMA y 4) Identificar factores predictores de DMA para intentar estratificar a los pacientes por riesgo. Ambito:Medicina a Intensiva de los 4 hospitales participantes Pacientes: Se incluirán de forma consecutiva 40 pacientes con NCG sin antecedentes de cardiopatia (20 NCG neumocócicas). Se incluirán 10 voluntarios sanos (controles). Se registrarán los datos epidemiológicos, clínicos y hemodinámicos. Se evaluará presencia de DMA y ECV mediante ecocardiografía, RMN y biomarcadores durante estancia en UCI y la presencia de fibrosis miocárdia (RMN) en UCI y a los 6 meses de evolución. Análisis de datos: Variables categóricas mediante test exacto de Fisher. La diferencia entre variables continuas por Wilconxon y Anova. La correlación de Pearson (correlación), ROC (poder discriminante) y regresión logística (asociación independiente) se usarán para estudiar la asociación entre variables y evolución. Se considerará significativo un valor de p <0.05 (Spanish)
    0 references
    Scenario: De novo cardiovascular events (VEC) in patients with severe community pneumonia (SCP) are frequent (17 %) and may be related to direct myocardial pneumococcal invasion, to the release of toxins (pneumolisin) or to exposure to endogenous protein released by the immune system (histones, NETs, IL-1b, h-FABP). The frequency of occurrence and its impact on evolution in patients without prior heart disease (PC) has not been studied. Objectives: 1) To determine the incidence of acute myocardial damage (AMD) and CVD in patients with non-invasive NCG without CP (Eco and Resonance MN) and biomarkers (Tn-I, h-FABP, NT-proBNP, histones, NETs, IL 1b, h-FABP); 2) To assess whether AMD and CVD are related to the causal pathogen of CAP and its impact on evolution and 3) to investigate the presence of myocardial fibrosis using MRI and its relationship with etiology and AMD and 4) to identify predictors of AMD to attempt to stratify patients by risk. Ambito:Medicina to Intensive of the 4 participating hospitals Patients: 40 patients with NCG without a history of cardiopathy (20 pneumococcal NCG) will be included consecutively. 10 healthy volunteers (controls) will be included. Epidemiological, clinical and hemodynamic data shall be recorded. The presence of AMD and CVD will be evaluated by echocardiography, MRI and biomarkers during ICU stay and the presence of myocardial fibrosis (MRI) in ICU and 6 months of evolution. Data analysis: Categorical variables using Fisher’s exact test. The difference between continuous variables by Wilconxon and Anova. Pearson correlation (correlation), ROC (discriminatory power) and logistic regression (independent association) will be used to study the association between variables and evolution. A value of p &LT;0.05 shall be considered significant (English)
    14 October 2021
    0 references
    Tarragona
    0 references

    Identifiers

    PI16_00486
    0 references